Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04000529 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT04000529 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 122 participants.
The verdict
NCT04000529, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment was administered until the subject experienced unacceptable toxicity, progressive disease, and/or had treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.
Interventions
- DRUG Ribociclib
- DRUG Spartalizumab
- DRUG TNO155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2024-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04000529
The ClinicalTrials.gov registry entry for NCT04000529 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribociclib is the first listed.
NCT04000529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04000529 about?
NCT04000529 is a clinical study titled "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies". This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two treatment arms enrolled subjects in parallel to characterize the ...
What is the current status of trial NCT04000529?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2019-07-30. Estimated completion is 2024-01-15.
What interventions are being tested in trial NCT04000529?
The interventions under investigation include: Ribociclib (DRUG), Spartalizumab (DRUG), TNO155 (DRUG).
Who is sponsoring clinical trial NCT04000529?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.